EMD-16383

Single-particle
2.9 Å
EMD-16383
3D View Gallery
Deposition: 21/12/2022
Map released: 19/04/2023
Last modified: 19/04/2023
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-16383
Download
3D volume (map.gz) Experimental metadata (xml)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 8c1v summary report (pdf.gz) Map and 8c1v FULL report (pdf.gz)
EMICSS annotations (xml)

Cryo-EM map of SARS-CoV-2 S-trimer (3 RBDs up) in complex with neutralizing sherpabody TriSb92

EMD-16383

Single-particle
2.9 Å
EMD-16383
3D View Gallery
Deposition: 21/12/2022
Map released: 19/04/2023
Last modified: 19/04/2023
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Severe acute respiratory syndrome coronavirus 2, Homo sapiens
Sample: SARS-CoV-2 Spike in open conformation with bound sherpabody
Fitted models: 8c1v

Deposition Authors: Huiskonen JT , Rissanen I , Hannula L
Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants.
Makela AR, Ugurlu H , Hannula L , Kant R , Salminen P , Fagerlund R, Maki S, Haveri A , Strandin T , Kareinen L, Hepojoki J , Kuivanen S, Levanov L, Pasternack A , Naves RA, Ritvos O , Osterlund P , Sironen T , Vapalahti O , Kipar A , Huiskonen JT , Rissanen I , Saksela K
(2023) Nat Commun , 14 , 1637 - 1637
PUBMED: 36964125
DOI: doi:10.1038/s41467-023-37290-6
ISSN: 2041-1723